Harrow, Inc. (HROW) Earnings Call Transcript & Summary

November 10, 2026

NASDAQ US Health Care Pharmaceuticals earnings 63 min

Earnings Call Speaker Segments

Mike Biega

executive
#1

Thanks, operator. Hello everyone, and thanks for joining Harrow's conference call covering results for the third quarter of 2026. This is Mike Biega, and I serve as Vice President of Investor Relations and Communications. Statements made by the company could include forward-looking statements, which federal securities laws define as such. Statements like these involve a variety of risks and unknowns, and a lot of them are beyond Harrow's ability to control. These include the kinds of risks and uncertainties that Harrow spells out periodically in what it files with the SEC — for example, matters concerning whether the company can bring its FDA-approved products, along with its compounded formulations and technologies, to market commercially, and whether certain drug candidates will win FDA approval promptly, or ever. If you'd like a full list and description of these risks and uncertainties, take a look at the Risk Factors section in the company's latest annual report on Form 10-K, as well as the quarterly reports on Form 10-Q it has since filed with the Securities and Exchange Commission. What actually happens at Harrow could end up significantly different from what's been projected. Harrow states that it has no intent or duty to refresh or amend any financial projections or forward-looking statements, whether due to fresh information, later events, or any other cause; the details on this conference call are time-sensitive and hold true solely as of today. Also, Harrow will reference non-GAAP financial metrics, specifically Adjusted EBITDA. A reconciliation of any non-GAAP measures against the most directly comparable GAAP measure appears in the company's earnings release and letter to stockholders, and both documents can be found on the website. With me on today's call are Mark Baum, Founder, Chairman, and Chief Executive Officer; Andrew Boll, President and Chief Financial Officer; Patrick Sullivan, Chief Commercial Officer; and Amir Shojaei, Chief Scientific Officer. With that, I'd like to hand the call over to Mark. Mark?

Mark Baum

executive
#2

Thanks, Mike, and good morning, everyone. In the prior quarter, I made it clear that our focus was converting the demand we were generating into revenue. In Q3, that is precisely what occurred, and it stands as the strongest evidence so far that the second half is unfolding as we anticipated. Demand is rising across key products, our expanded commercial team grows more productive with each passing month, and we are reaffirming guidance for full-year revenue. The momentum continues, and I expect Q4 to rank as the strongest quarter in Harrow's history. I also believe that momentum will carry into 2027. You can see it in VEVYE, which posted record revenue as our expanded sales force matures and starts delivering improved prescription economics. You can see it in TRIESENCE, which enjoyed its best quarter since coming under Harrow ownership. You can see it in IHEEZO, which enters its historically strongest quarter backed by new clinical evidence from QUELL. A key part of this story is how we are structuring our commercial business to maximize the opportunities ahead. With TYRVAYA added, we reorganized our commercial operation into four focused teams: ocular surface disease, retina, surgical, and access plus, each organized around the same prescribers, care settings, and purchasing dynamics. Our biggest team now serves one of our largest opportunities, namely ocular surface disease, including dry eye, where we currently own two fully differentiated products in the category. Our new commercial structure lets our representatives promote a wider portfolio of complementary products to the same customers, making each relationship and each sales call more productive; commercial leverage has always worked in our favor, but this organization elevates that advantage to another level; with the HarrowRx launch, we are making it even simpler for those customers to reach our full portfolio via a single destination integrated into their existing workflows, primarily their EMRs. The G-MELT program, launched more than 10 years ago, has truly been a labor of love and is the first program Harrow carried from idea all the way to an NDA filing in a matter of weeks. Once our NDA is accepted for review and we receive our PDUFA date, which hopefully will come in 2027, it will represent a tremendous accomplishment for the whole Harrow family and for our stockholders alike. I am thrilled that we will soon, hopefully, have the chance to reduce or eliminate the need for IVs and opioids in cataract surgery for millions of Americans each year. Amir will cover our NDA filing in a bit more detail shortly. In summary, Harrow today has more products, stronger commercial capabilities, and more avenues for growth than at any other point in our history, but we are not finished building. We are not finished building, yet the emphasis has moved from constructing the platform to excellence in commercial execution and delivering financial results. With that, I will hand it over to Andrew to walk through the financials and our outlook. Andrew?

Andrew Boll

executive
#3

Morning, everyone, and thanks for being on the call today. For the third quarter, revenue hit a record $99.3 million, which is up 41% sequentially and 39% year-over-year. Branded revenue came in at $83.5 million, an increase of about 62% year-over-year, and accounted for roughly 84% of total revenue. VEVYE brought in $39.7 million, IHEEZO contributed $25.3 million, and TRIESENCE generated $10.7 million in revenue. Compounded revenue stood at $15.8 million. VEVYE really demonstrated how demand turns into revenue. Its revenues rose 35% sequentially, growing faster than prescriptions as the changes we made to prescription economics kicked in. GAAP gross margin was 75%, in line with a year ago and better than the 71% we saw in Q2. That said, our gross margins remain below what we expected, and that's mostly because of lower gross margins from our compounding revenue and product mix. SG&A came to $53.1 million, which reflects our expanded commercial organization and was roughly flat quarter-over-quarter. R&D was $10.3 million, a bit above our expectations, but that's because programs are accelerating and arriving ahead of schedule, mainly reflecting G-MELT NDA enabling work along with clinical studies for IHEEZO and TRIESENCE. We also booked a one-time $5 million gain, shown as other income in our statement of operations. That relates to resolving and settling our litigation with OSRX that goes back several years. GAAP net income was $9.8 million, and Adjusted EBITDA was $21.2 million, compared with an Adjusted EBITDA loss of $1.2 million in Q2. We finished September with $75.3 million in cash and cash equivalents. Now to our outlook: we are reaffirming full-year revenue guidance of $350 million-$365 million. That implies Q4 revenue of roughly $136 million-$151 million, or approximately 37%-52% sequential growth; it's a big step-up, and here's why we think it's achievable. Across the past two years, Q3 to Q4 revenue growth averaged approximately 30%. This year, we believe we're heading into the fourth quarter with significantly more momentum across our portfolio. VEVYE is gaining from expanded insurance coverage, a larger sales force, and improving prescription economics. IHEEZO is heading into its historically strongest quarter, while TRIESENCE keeps building traction in ocular inflammation, backed by our expanded surgical team, and BYOOVIZ sales are rising. Beyond that, TYRVAYA is a new revenue contributor, having started contributing revenue in the fourth quarter. All together, these drivers give us confidence in our ability to deliver a strong finish to the year. On profitability, we're updating our full-year Adjusted EBITDA outlook to more than $40 million, including more than $33 million in the fourth quarter, versus our previous guidance of $80 million-$100 million. Let me give some context on that change. Our first-half revenue shortfall and lower gross margins than we anticipated left us behind our original EBITDA expectations. Back then, we could still see a route to hitting our guidance, though it called for a really strong second half, one that included a favorable mix of products with higher margins; during Q3 we made meaningful progress, delivering $21.2 million in Adjusted EBITDA and lifting our year-to-date total to $7.3 million. Even so, reaching the low end of the guidance we had previously given would still require roughly $73 million in Q4 by itself, and our third-quarter performance simply was not where it needed to be. As we worked through our fourth-quarter forecast, a number of things have changed as well; we are moving forward with our G-MELT NDA submission this year, which pulls the FDA filing fee and preparation-related expenses into Q4. We have also accelerated spending across several clinical and development programs, including QUELL, the phase III TRIESENCE study, and Yochu. And we are absorbing transition costs and purchase accounting impacts tied to the TYRVAYA acquisition. Mark and I believe that speeding up these initiatives is the right call for the business, even though it affects near-term profitability. Instead of depending on an unusually favorable fourth-quarter product mix to offset those added costs, we have set a more conservative Adjusted EBITDA outlook that reflects our current expectations. Importantly, what we are providing is a floor, not a range. Our expectation is for more than $33 million in fourth-quarter Adjusted EBITDA, and there is room to outperform that level depending on how the quarter develops. We are confident in the underlying momentum of the business and believe these investments will position us well heading into 2027. I will now turn things over to Pat to discuss some key commercial achievements and metrics.

Patrick Sullivan

executive
#4

Thanks, Andrew, and good morning. Beginning with VEVYE, total prescriptions rose 17% from the prior quarter and 83% compared with a year earlier. Two things stand out. First, we expanded the field team supporting VEVYE to more than twice its size this year, and the newer reps are getting more productive within their territories. The second is economics. Our emphasis has been on helping more patients obtain covered therapy, and that effort is paying off. Covered prescriptions are climbing, with encouraging gains among Medicare patients that carried into October. This is enhancing the economics of each VEVYE prescription, and we continue to add coverage. We recently broadened coverage via a major national plan that covers roughly 10 million lives, effective January. That marks our third coverage win this year and bolsters our position as we head toward 2027. TYRVAYA's integration is coming along well too. About 40 seasoned sales representatives and their managers have come to us from Viatris and are already visiting many practices they know well; under Harrow, we're starting to see prescription demand increase. Now turning to IHEEZO. Unit demand came in at 62,210, a rise of 21% year-over-year. Demand came in about 5% below the all-time high we saw in Q2. Two things explain that: procedure volumes are traditionally lighter in the third quarter, and practices had stocked up heavily on the earlier single-unit presentations late in Q2. Even with that decline, we expect demand to grow sequentially, and we believe Q4 has a shot at setting a fresh quarterly record. The fundamental IHEEZO momentum is still solid. Our customer roster continues to grow, and gains at new retina accounts, plus deeper penetration within accounts we already serve, have more than offset the units we gave up once pass-through status expired in the ASC setting. As Amir will discuss next, QUELL provides our retina team with something unprecedented: prospective, randomized data regarding IHEEZO and intravitreal injections, including encouraging results on patient comfort and tolerability for those returning for injections month after month. Now turning to BYOOVIZ. BYOOVIZ expanded broadly before deepening. A greater number of practices submitted initial orders than we expected, though many started small as they validated reimbursement and purchasing. Early reimbursement experience has proven favorable. Multiple accounts have reordered, and demand grew stronger throughout September and into Q4. Our focus is converting initial orders into larger, more consistent purchasing—insights that will shape the OPUVIZ launch in 2027. Now let's discuss TRIESENCE. Unit demand came in at 20,022 — that's a 37% increase from the prior quarter and 110% higher than a year ago, making it our best quarter since we brought the product back to market. Ocular inflammation is a major factor here, and it's particularly encouraging to see practices starting to incorporate TRIESENCE into their treatment protocols, since that generally leads to more consistent and predictable usage and unit volumes over time. For the fourth quarter, our priorities are well defined: we'll build on VEVYE's momentum and its improving economics, push IHEEZO's growth during its strongest season, drive deeper adoption of BYOOVIZ, deliver TYRVAYA's first quarter under Harrow, and keep growing TRIESENCE along with the rest of our portfolio. We head into the quarter with more avenues to win than we've ever had, and our team is prepared. With that, I'll hand things over to Amir.

Amir Shojaei

executive
#5

Thanks, Pat. I’ll discuss QUELL and G-MELT. Today we are reporting topline results from QUELL, our phase IV, multi-site, randomized, double-masked trial that compared IHEEZO against routine anesthesia in 231 patients who were undergoing intravitreal injections. I’ll begin with the primary endpoint. QUELL failed to meet its primary endpoint of non-inferiority. Successful ocular surface anesthesia served as the primary endpoint, and it was defined as a pain score of 0, which means no pain, or 1, which means pressure only, at both immediately before and immediately after the injection. That outcome was achieved by 55.2% of patients on IHEEZO versus 59.7% of those receiving routine anesthesia, and the upper bound of the 95% confidence interval went beyond the 12-point margin we had pre-specified. Design context is important here. The study assumed that 88% of patients in each arm would achieve success. The overall rate actually observed was only about 57%. At that rate, approximately 114 patients per arm could not yield a confidence interval narrow enough to fall within a 12-point margin. Put differently, the primary endpoint was inconclusive. The study did not show that IHEEZO was non-inferior, but it also did not show that IHEEZO was inferior. For retina specialists and their patients, comfort, pain, and safety matter critically. That is where QUELL’s exploratory secondary and safety findings are encouraging. Bear in mind that routine anesthesia in this study consisted of proparacaine drops followed by a potent subconjunctival lidocaine injection—essentially an injection before the injection. Despite that difference in how anesthesia was given, cumulative pain scores at immediately before and immediately after the intravitreal injection were identical at 2.0 in both groups. Differences began to emerge after the procedures. Patients on IHEEZO reported less pain in the hours after the injection, with cumulative pain scores through 24 hours of 2.9 versus 3.7 for routine anesthesia. We also saw encouraging findings regarding ocular surface health. Patients on IHEEZO showed less ocular surface staining after the procedure, with a mean increase of 1.7 versus 3.2 for routine anesthesia. This suggests less damage to the ocular surface with IHEEZO. Importantly, staining in the untreated eye stayed unchanged in both groups. Finally, looking at patient-reported dryness symptoms as measured by the SPEED questionnaire, patients on IHEEZO had less worsening on the day of the injection, and by 24 hours their symptoms had improved from baseline. To me, this shows why the primary endpoint does not tell the whole story. It measured whether patients met a pre-specified threshold at two time points, but it did not fully capture differences in pain and ocular comfort over the hours that followed. We also observed fewer adverse events with IHEEZO, 27% versus 47%, with no serious adverse events in either group. I want to extend our sincere appreciation to all the investigators and all the patients who made this study possible. Overall, I am encouraged by these data. All in all, those give us useful new clinical data on IHEEZO for intravitreal injection procedures, and we're eager to share the complete findings at the Hawaiian Eye & Retina Conference in January 2027. Regarding G-MELT, we've finished our pre-NDA meeting with the FDA and are still on schedule to file the NDA later this month or at the start of next month — notably sooner than we had initially anticipated. Should it be approved, G-MELT has the potential to be the sole on-label product for sedation during cataract surgery, offering patients effective sedation with no IV line and no opioids in one of the most frequently performed surgical procedures in the U.S. With that said, I'll hand the call back to the operator for questions.

Chase Knickerbocker

analyst
#6

Good morning, and thanks for taking our questions. Perhaps to begin with VEVYE—congratulations on the continued progress there. Could you go into more detail about some of those business changes you made in September, given the effort to improve the product's net realized ASP? Thanks.

Mark Baum

executive
#7

Hi, Chase; Mark here. Thanks for the question. I appreciate it, but we're in an intensely competitive market, and unfortunately I'm going to elect not to answer. We don't want to reveal the specific algorithm that we use in order to improve VEVYE economics.

Chase Knickerbocker

analyst
#8

Got it. Perhaps only if you anticipate that effect showing up clearly in Q4 as a result of those modifications to the business rules.

Mark Baum

executive
#9

Well, I can say with certainty that improvement is definitely visible in prescriptions covered by Medicare, and honestly, I believe it's happening broadly. The count of practices ready to file prior authorizations on behalf of their patients so they can get VEVYE is in fact far greater than you might expect; and importantly, the volume of prior authorizations being approved, even in cases where coverage is absent, is substantial. This is, I'd say, across the past 60, 75 days, the first genuinely coordinated push our team has made to change the balance between covered and cash pay prescriptions. As we mentioned during the call, the data is highly encouraging. The economics of VEVYE are definitely getting better. They improved during the third quarter, and I think you'll witness that in the fourth quarter too. Andrew, would you like to add anything?

Andrew Boll

executive
#10

That's all from me, Mark.

Chase Knickerbocker

analyst
#11

Next, on your view of where things stand with that bigger commercial team and VEVYE's productivity — obviously volume growth remains impressive, plus there's the lift the new TYRVAYA reps bring to the franchise overall. Then my second and final question, Mark Baum: given that coverage win in Q1, should we view its effect as comparable to what the CVS win delivered in Q1, letting us buck some of the seasonal volume patterns in Q1? Thanks.

Mark Baum

executive
#12

Sure. I'll address the second question, since as you're aware, one major factor behind the significant shortfall we experienced during the first half of this year—something I noted in the stockholders letter—was the difficulties we encountered regarding market access with that large coverage win. With this new coverage win starting next year, I don't think you'll encounter those identical problems. In fact, while I don't wish to make a guarantee, I can nearly assure you that we won't experience that same degree of impact. So this represents a substantial win, and I believe you'll observe once more a larger transition from prescriptions paid in cash to prescriptions that are covered. When it comes to a prescription that's covered, our overall economics are significantly better than what we get on a cash pay prescription. So this recent coverage win has us very excited, and so do the additional coverage wins we've secured with even smaller plans. We're therefore making genuine progress. We made a commitment to advance on covered prescriptions. I believe we're fulfilling that commitment, and I believe you'll see ongoing progress on coverage for VEVYE in 2027. That would be a fresh forecast. I think additional coverage for VEVYE is coming your way. There appears to be solid momentum in that area. Regarding how productive the sales force is, Pat, do you want to address that?

Patrick Sullivan

executive
#13

Absolutely. Thank you, Mark, and I appreciate the question. Our new ocular surface disease team is out there representing Harrow's portfolio, and we couldn't be more enthusiastic or optimistic about them. What I'd say is that the products this team represents genuinely provide the ophthalmic community with a full suite of solutions, and that aligns quite well with our aim of becoming the preferred partner going forward. Our combined team is at a really early stage in this process right now, but I'd describe it this way: given how we've structured our footprints and our engagement plans, it's early days, yet we're feeling very, very positive about the trends we're seeing initially, the feedback coming from physicians, and ultimately the integration is proceeding smoothly. So Q4 has us quite encouraged by what we're seeing in these early days, and we look forward to strong results as we continue building on Q3.

Chase Knickerbocker

analyst
#14

Thank you.

Mark Baum

executive
#15

That's great. I think I'm excited because if you consider where we stood at the start of the year in terms of how many key account managers were covering VEVYE compared with today, that number has more than tripled. If you look at the reps covering TYRVAYA before Harrow acquired it versus now, it's basically doubled. Beyond that, two other products where we're seeing real momentum in prescription volumes are VERKAZIA and NATACYN, and those two now sit within that ocular surface disease team. We have all of those reps now, and these aren't hard push sales. With fungal infections, and this being the only FDA-approved product for that condition, docs simply need to know how to get access to NATACYN. When patients have severe allergies, children have severe allergies, and doctors don't want to prescribe steroids for those patients, this is really the only steroid-sparing product, VERKAZIA. Our reps are now letting them know it's available; so we have a lot more people providing that access information, and I think you're going to see those big four products, the biggest being VEVYE, really leverage this increased sales force.

Lachlan Hanbury-Brown

analyst
#16

Hey, guys. Thanks for asking. I guess first, maybe I just wanted to follow up on QUELL and kind of expand on what it means for IHEEZO in retina. Are you thinking about doing another study, or where do you go from here? Do you need another study? Does this affect the plans to get it on the label? I guess if we could just start with your thoughts on that.

Mark Baum

executive
#17

Yeah. For us — and I'll also ask Amir Shojaei to comment — for us, the key here is medical messaging. The reason we invested in the study isn't only to get a label amendment, if possible, if that made sense, but I think the critical piece is medical messaging. Being able to send a sales force out to talk about how our product is used specifically in the intravitreal injection procedure — we haven't had that until now. Every study that was done for IHEEZO was done in cataract surgery. Now, we do have a robust data set for intravitreal injections. What we learned, I think, is that it's pretty hard to anesthetize the eye and get a zero or one pain outcome not only with IHEEZO but also with an injection of lidocaine. It's not easy. If you look at the data, I mean, we came within four patients, or 4 percentage points, of being equivalent to an injection — sort of mainlining the anesthesia into the eye. I was quite proud of how the drug performed. But the key for us is those secondary endpoints — being able to go out to an office and say, "Look, your patients will have less pain after the injection from hours four to 24 hours, better ocular surface staining, and far fewer adverse events." We can now say that confidently and legally. Amir Shojaei, anything you want to add to that?

Amir Shojaei

executive
#18

Once more, the sole point I would add is that at present we have no plans for a second study or additional studies in this line. Having said that, we do have a fair number of ongoing studies involving investigator-initiated trials across the IHEEZO franchise.

Lachlan Hanbury-Brown

analyst
#19

And as a follow-up question, I saw some remarks in the Form 10-Q regarding the licensing of TYRVAYA possibly violating certain provisions of the VEVYE licensing agreement with Novaliq. I'm just curious what the possible outcomes might be there. For instance, could this end up requiring a divestiture of TYRVAYA? I understand you likely can't comment much, but could you offer us any clarity on what this might mean?

Mark Baum

executive
#20

Yeah. Well, let me start by saying that Novaliq and Harrow have been a match made in heaven. We've been an outstanding partner to them. They've been an outstanding partner to us. If you look at the growth in VEVYE units and the progress our team has achieved with that product, I think it's very hard to reach any other conclusion. It's simply been an outstanding relationship on both sides. When it comes to TYRVAYA, we are bound by confidentiality. We're in active discussions with them. I think we believe, and I also think they believe, that adding all of the salespeople and the investments we've made as a result of the TYRVAYA acquisition really do benefit sales of VEVYE. So, we're going to work through this process, and I would bet that once we're done, we'll probably have a stronger relationship with our partners at Novaliq than we do today.

Lachlan Hanbury-Brown

analyst
#21

Thank you.

Steve Seedhouse

analyst
#22

Morning, and many thanks for asking. I'd like to explore BYOOVIZ a little more closely; from what you said, it sounds as though you had a pretty clear internal picture of what the launch would deliver, and you noted wider breadth but perhaps less depth in the early order flow. Could you say more about that, perhaps take us through what it implies from here, and I'd also like to hear what you've picked up so far and how that shapes what you expect when OPUVIZ arrives next year.

Mark Baum

executive
#23

Okay, I'll bring Pat in for a comment shortly, but my take would be this: whenever you bring a biosimilar into a category that's already fairly competitive, the honest answer is that you simply can't predict what the uptake will look like. Our retina relationships are very strong; the retina team we have is incredible, so the Harrow family members working on the retina side are simply extraordinary when it comes to their productivity, the relationships they've built, and the trust they've earned with customers over many, many years — in most cases, certainly long before they became part of the Harrow family. You're right, though—at launch we were broad but shallow. That can be concerning in one way, but the fact is a large number of physicians bought the product, far more than we had originally projected. So the real question becomes whether you can generate repeat demand following those first orders. And they won't hand you that revenue chance, those volumes, until they've been through essentially the same buy-and-bill process we've observed with IHEEZO, with TRIESENCE, and with our other products in the buy-and-bill segment. So once they completed that cycle, we did observe—and we're still observing today—that follow-on buying, and I believe that's the key point I can share on this call regarding BYOOVIZ: those repeat purchases are coming in. In Q4, we're likely considerably ahead of our model, while in Q3 we were a bit behind. Still, the chance to move more units to more customers can definitely let you close that gap fast. Pat, anything you'd like to add?

Patrick Sullivan

executive
#24

Absolutely. Thank you, Mark, and I appreciate the question. As Mark noted, during the launch's early phase in Q3, we picked up a tremendous amount of learning. One thing that sets Harrow apart is our capacity to stand out — unlike other companies in the retina space that have biosimilars, we can draw on our other products, such as IHEEZO and TRIESENCE, which gives us a distinctive way of engaging. With BYOOVIZ specifically, as Mark said, one point we know is that biosimilars are interchangeable, and that is a genuine advantage, so our emphasis is squarely on taking share from the originator where BYOOVIZ is concerned. But one thing we do observe is that early in the buy-and-bill cycle — as Mark alluded to — accounts and physicians will still work through that process of, even though it is a common molecule, they will work through the process of, first, confirming reimbursement and all those various details that give them added confidence. We are past that stage at this point, and we have very clearly segmented our business in Q4 to concentrate on growth, and, as Mark said — to restate it — we are seeing early signals in Q4, with acceleration building on Q3.

Mark Baum

executive
#25

And —

Steve Seedhouse

analyst
#26

Great.

Mark Baum

executive
#27

— when it comes to the market opportunity for OPUVIZ and the EYLEA 2 mg biosimilar, in terms of volume, it's meaningfully higher. The count of accounts that will use OPUVIZ is significantly higher than the ones that use BYOOVIZ.

Steve Seedhouse

analyst
#28

Yeah, just to follow up on the reimbursement and net price side of things for BYOOVIZ, how has that gone relative to your expectations?

Mark Baum

executive
#29

Andrew, do you want to comment on that? I don't know that we can give a lot of color on net pricing, but maybe contracting.

Andrew Boll

executive
#30

Yeah

Mark Baum

executive
#31

progress.

Andrew Boll

executive
#32

Steve, building on what Mark said, we won't be discussing the product's net pricing, simply because of how competitive things are. As for coverage, though, I'd say we're genuinely happy with what we've secured for the product. Related to your earlier question on lessons learned ahead of the OPUVIZ launch, that effort involves a great deal of learning as well—on the market access front and with payers—and I believe that will work strongly in our favor. Even so, payers have been fairly receptive up to now. I've been pleased, and I think the commercial team shares that view regarding payer uptake.

Steve Seedhouse

analyst
#33

Many thanks.

Tom Shrader

analyst
#34

Morning. Great to hear about all that progress. I've got a couple of closely linked questions about BYOOVIZ. Do you have a good read on what the folks testing things out are actually after? Is it help with reimbursement? Is it that your supply chain is straightforward? Any idea what they're seeking?

Mark Baum

executive
#35

Well, we haven't actually surveyed the accounts, but broadly speaking, with a buy-and-bill product, as I mentioned, it's the same kind of purchasing cycle we've observed with IHEEZO, with TRIESENCE, and honestly with all our buy-and-bill products. They purchase the product, but they have to be confident that once they buy it, they'll get reimbursed. So succeeding on the buy side is one thing, but remember, it's buy and bill, and the billing part has to come through. That's a crucial element they're looking into when they make these first purchases. And we are seeing that follow-through, which really matters, and it's reflected in the fourth quarter numbers for BYOOVIZ, and we'll carry all those learnings into 2027 when we launch OPUVIZ. Bear in mind, Tom, we hold the biggest portfolio of buy-and-bill products across all of ophthalmology. I don't believe any other company has as many buy-and-bill products as we do. So our team brings remarkable experience on the buy-and-bill side of things.

Tom Shrader

analyst
#36

Now regarding the QUELL trial — for a mixed trial of that kind, is the principle that once you manage to get it published, you're free to market the data and, say, emphasize whichever pieces you choose? Are there any restrictions on what's permitted with a mixed trial like that? And one quick follow-up, just on TRIESENCE: of the original market, back when the other players had it at peak, how much have you captured by now? Thanks.

Mark Baum

executive
#37

Sure. Well, I'll handle the second question and hand the first one over to Amir. As for TRIESENCE, it's being used in an area — inflammation for ocular surgery — that we know very well inside our company. That's the foundation of how we launched this company. We began selling compounded triamcinolone acetonide to the cataract surgery market as a compounded medication back in 2014. So we have an enormous amount of history. That compounded product has been used in more than 1 million cataract surgeries by thousands of ophthalmologists across the U.S. market. So we understand this space exceptionally well — the size, the addressable market, the opportunity. Even though we reported 20,000 units in the third quarter, that's really a very small percentage of the total market opportunity for that product. I've been talking about how confident we are in TRIESENCE for, I guess, a couple of years now. Look, the units and the volumes in the quarters after I started talking about how excited I was to relaunch TRIESENCE weren't very impressive. What I think you're beginning to see is that the overall assessment I had a couple of years ago was on track. It was just a little bit late, and you're starting to see that pick up. It isn't easy to grow sequentially the way the unit volumes for TRIESENCE are growing now. We have an incredible team. The surgical team has done a wonderful job — Chad and Mike and the rest of the team. We're very bullish on TRIESENCE continuing to grow. I think our penetration is certainly in the low single digits; we've got a lot of headroom with TRIESENCE. The key factor, before I turn it over, is the clinical outcomes. The clinical outcomes anecdotally on the use of TRIESENCE — all of these new use cases that are driving this increase in volume — the clinical outcomes are extraordinary. They're outstanding, the one-day post-ops that we hear about anecdotally. What we're really excited about is that Amir has this TRIESENCE study going, and we're going to be able to, once again, just like with IHEEZO and the QUELL study, go from the anecdote to the actual. We're going to have a data set to present that I think is going to fuel further adoption of TRIESENCE; that was a long answer, but I do want to turn it over to Amir on QUELL to comment.

Amir Shojaei

executive
#38

Appreciate the question. The way I'd frame it is that the data review is really at its earliest stage at this point. Top-line results are in hand, and we expect to have the complete dataset. As you mentioned, the study will be published and presented. Once that happens, the core premise behind the study would be medical messaging. Our medical team is very strong, and we'd be communicating this through the relevant media and conferences. Overall, this study carried the rigor needed for publication in a peer-reviewed journal, so we expect to go that route together with the investigators involved. That's our plan.

Tom Shrader

analyst
#39

All right, great. Appreciate all the details.

Dan Clark

analyst
#40

Great. Thanks. Good morning. My first question is about the 2026 revenue guide. I'm just curious what scenarios you're considering to reach the high and low ends of the sales range here. Thank you.

Mark Baum

executive
#41

Andrew, would you like to take that one?

Andrew Boll

executive
#42

Sure, Daniel — I’ll give it my best shot, though we typically don’t offer guidance at the product level. We discussed the path to those numbers at length in the shareholder letter and in the deck. From VEVYE, we anticipate quarter-over-quarter growth. TRIESENCE will keep contributing. IHEEZO should also show sequential growth. As we’ve discussed quite a bit during the Q&A, BYOOVIZ is still growing as we head into Q4, and based on the early momentum we’ve observed, Q4 will be a really strong quarter for that product; then you have TYRVAYA’s contribution. I realize we didn’t give quarterly guidance on TYRVAYA, but the MD&A in the Q makes clear that we expect more than $30 million in revenue from that product next year. That product is a pharmacy benefit product, and it will have its strongest quarter in Q4. So we benefit from that product’s best quarter landing at the close of 2026 and adding revenue where we didn’t have that benefit earlier in the year. Then, we’re always working on things, so there are some other commercial-side aspects of the business we’re developing that could help us push past the low end of the guided range.

Dan Clark

analyst
#43

All right, understood. That's really useful. As a quick follow-up on HarrowRx, I'm just wondering whether there are specific products or use cases where you see this making a meaningful difference to the provider experience, and it would be great to hear how you're viewing the opportunity this launch presents. Thanks.

Mark Baum

executive
#44

Absolutely. Appreciate the question, Daniel. HarrowRx is genuinely a key platform for us — when I'm out traveling and speaking with our sales reps, who are in offices daily and meet especially with the staff there who grapple with the difficulties of prescribing pharmacy benefit products, they'll be using one specialty pharmacy for a competitor's product. For VEVYE, for instance, they use a separate specialty pharmacy. Luckily, TYRVAYA was offered through PhilRx, our specialty pharmacy partner. But here's what we can give those offices — and this is what I hear constantly, every single day, in conversations with our customers — they're consistently taken aback by how broad our portfolio is. It surprises them that we carry NATACYN, that VERKAZIA, ILEVRO, and FLAREX are ours. The list goes on. What draws their interest is having one single access point covering our whole portfolio; going forward, at Harrow we believe a greater share of prescribing will happen via these kinds of specialty hubs. Suppose you got a prescription for ILEVRO and sent it to your nearby CVS — chances are that product isn't in their stock for pickup within an hour or two, so they'd need to order it. Looking ahead, if we're able to deliver that one access point across this very sizable product portfolio — I think we're now above 20 branded products — we believe that makes a highly appealing platform for physicians and their staff to use, letting them handle prior authorizations and every other feature we've got planned for it. It's going to be a significant piece of our business. It will serve as one access point spanning our entire portfolio, and I don't think any of our competitors truly offers anything comparable.

Mayank Mamtani

analyst
#45

Yes. Morning, everyone. Appreciate you taking our questions, and thank you for the thoroughness here. If I could ask about the new patient start trends for VEVYE, Mark—those look strong. Could you say something about where they're coming from? Are they switches from generic cyclosporine or from other branded options, or are they patients new to prescription treatment? I'm curious whether the mix is shifting at all now that your sales force is fully deployed and payer coverage keeps expanding.

Mark Baum

executive
#46

Yeah. Honestly, we don't know what's driving the stability and growth in our new prescription volumes. At the time we rolled out these rules, our expectation was that volumes could fall off—that we might need to sacrifice volume in exchange for improved net pricing. Luckily, that simply hasn't materialized. Even with the new rules in place, we've actually been able to increase new prescription starts—this new algorithm that enhances net pricing, and it is enhancing net pricing for us. I'd call that a genuinely encouraging development for the VEVYE franchise. Regarding where those patients are coming from, as I mentioned, we don't know. When I administer VEVYE to my own eye—and I do—and then try the alternative options in my eye, I can't understand why anyone would begin with anything other than VEVYE. It feels wonderful, acts quickly, and delivers a lasting treatment effect. The numbers are amazing, and honestly it feels fantastic. Like I mentioned, I can't understand why somebody would choose anything besides VEVYE, though a few still do. As I believe your question implies, an increasing number of patients are beginning treatment with VEVYE, and I anticipate that pattern will keep going.

Mayank Mamtani

analyst
#47

Great. Just a couple more, and I'll be quick. On the IHEEZO step-up in 4Q, whatever you can share, could you quantify the year-over-year figure, and also the restocking and the net price per unit reset that occurred in 2Q? Speaking broadly, should we view this through the lens of alternating quarterly buying cycles, where 2Q and 4Q come in strong? Or, when we think about next year — and I realize you aren't providing guidance for next year today — is it essentially a steady climb from 2Q through 4Q, with a sort of reset in 1Q? Then perhaps only for Amir, regarding the G-MELT NDA submission, which components have been accelerated, if you could weigh in, and any reflections from the pre-NDA meeting you might have had concerning how to approach the scheduling of the combination product, given that you're clearly getting ready for commercial readiness? Thanks for taking the question.

Mark Baum

executive
#48

Yeah. Mayank, thanks for the question. I'll offer a remark on IHEEZO and by not commenting or attempting to answer your question. We truly don't want to be in the practice, and I believe I mentioned this in the letter to stockholders, of providing quarterly guidance on a product-specific basis. IHEEZO in particular can be uneven from quarter to quarter. Even so, as we noted in the letter and I believe touched on during this call, Q4 is consistently the peak quarter for that product. Sure, Q2 looks solid and Q1 was decent enough; this year especially brought certain difficulties in converting IHEEZO into revenue, something we've addressed repeatedly on earlier calls. Come 2027, I expect expectations around IHEEZO to settle into a more normal pattern. There's one prediction I can offer regarding IHEEZO: volumes and revenue in 2027 will outpace 2026, much as 2026, at least where demand is concerned, ended up surpassing the year before. Amir, would you like to say anything about the G-MELT filing? I'm not sure there's much you're able to share regarding our pre-NDA meeting. Still, if we're really going to file with the FDA, it must have gone reasonably well.

Amir Shojaei

executive
#49

Yeah, I think I agree with that. It was a productive meeting, and we're aligned with—or more importantly, we're submitting what the FDA expects to receive. So in that respect, we're starting off on the right foot, and we'll be submitting, hopefully by the end of this month, if not the beginning of next month. That said, we anticipate a PDUFA goal date next year. Whether it's priority review or not, that'll be part of the decision the FDA makes. Beyond that, I think from a scheduling standpoint, that would also be a review during the submission. We're moving forward with our anticipated scheduling between the two fixed-dose combination products.

Mayank Mamtani

analyst
#50

Great, thank you very much, everyone.

Thomas Flaten

analyst
#51

Hi there, good morning. I have a few follow-ups. First, for Amir — and I'm sorry if I missed this — but do you have any theory as to why you fell roughly 30 points below the 88% anesthesia target you'd set for the study?

Mark Baum

executive
#52

Excellent question. Amir, would you like to take that one?

Amir Shojaei

executive
#53

Thank you for raising that. To be honest, this was the first group of adequate, well-controlled studies capable of producing that response to what you asked. Our view is that the hypothesis is really about the meaningful distinction between a procedure involving a cut to the eye versus one that calls for deep penetration into the eye. That is where the difference lies, and, as Mark hinted, it comes down to how you anesthetize the eye. Once you look across the different procedures, you see that the thresholds you would need to establish differ from one to another. We established our threshold by extrapolating from the data that existed, since nothing else was available; now that we have these data, we have clearly come to understand the actual benchmark at which we ought to have set the study. That is essentially the core of it. It was borrowed, or extrapolated, from another procedure, given that no other data existed.

Thomas Flaten

analyst
#54

Understood. I appreciate the—

Mark Baum

executive
#55

Let me just build on that, actually, since it's really fascinating. When IHEEZO came to market, the number of physicians who told us "Anesthesia isn't an issue" — I couldn't even count them. They'd say there's no problem here that you could help us fix. But I believe the QUELL data makes it plain: these injections cause patients pain. It strikes me as obvious that sticking a needle through someone's sclera would hurt. The study definitely proves that point; it further reveals that whether you numb the eye by injecting lidocaine — essentially one needle ahead of another — or you'd rather go with a topical option such as IHEEZO, you can bring patients to roughly an equivalent level. As a matter of fact, Amir mentioned that pain scores across the two cohorts came out basically identical, at two. What excites us, and what our medical team can now communicate lawfully, is the patient experience following the injection; it matters enormously that these practices avoid fielding calls from patients in pain — perhaps because they received a lidocaine injection after the procedure, or they have trauma to the ocular surface, or they suffered some other adverse event tied to the intravitreal injection. Being able to communicate that now means so much to us. Looking ahead, this is a data set that will work in IHEEZO's favor, that will serve our reps well; it will certainly support using IHEEZO in practice across a greater number of practices. We're genuinely delighted with the data set we invested in. It could have been better, by the way.

Thomas Flaten

analyst
#56

That means a lot to me. Thanks so much.

Mark Baum

executive
#57

Sure, it might have turned out stronger, yet all in all it was really quite impressive.

Thomas Flaten

analyst
#58

No, that's great. Thanks, Mark. Then a follow-up for Pat. You brought up the new territory design and the ocular surface team, but could you maybe expand on that a bit more? So, you've effectively got three teams coming together. You've got seven products. Are you overlapping in territories? Did you split territories to create more frequency in smaller groups? Can you talk a little more about what that territory design looks like and how your incentive compensation looks with a seven-product bag?

Patrick Sullivan

executive
#59

Yeah. Appreciate the question. On the earnings call before this one, and through earlier communications as I recall, this has clearly been a carefully staged, disciplined effort that began earlier in the year. As you'll remember, the organization made a significant commitment — and I believe this was to further grow our footprint in dry eye and to really support VEVYE — and that was earlier this year, as you'll recall. So at this point, what we've done is, to your point, we've brought together three teams, including the highly capable Viatris team that came with the TYRVAYA acquisition. As Mark mentioned, we had a specialty team representing a handful of our specialty products—the rarer ones he referred to, VERKAZIA and IOPIDINE—and we also folded that into our dry team. That's our ocular surface team. What I'd say is one thing we're genuinely excited about is how methodical we were, first in taking a really clear approach—first, reaching the right physicians to ensure we've got the right product prioritization, so the right promotional intensity delivers the outcome we're after. Our primary emphasis is very much on VEVYE. Looking at our prescription trends for VEVYE, growth came in quite strong versus the previous quarter at 17%, and I believe 83% year-over-year. We're genuinely excited that this is only the beginning, and early feedback on our new model keeps telling us that the way we're rolling it out is smart and sophisticated, which is lifting productivity. If I had to sum up where we're putting our focus, it's VEVYE first, along with the rest of our dry eye portfolio. I believe that by drawing on the other products we have, we're able to appear in a truly distinctive manner that only Harrow can achieve given how broad our product range is. If you consider it now, we hold a genuinely premium cornerstone position with VEVYE as the top dry eye disease product; adding TYRVAYA, FRESHKOTE, and FLAREX creates a truly distinctive mix within our portfolio. Let me be clear, VEVYE is our primary product, receiving the greatest emphasis and the heaviest promotional focus. In response to your question, we have a very well-defined plan. It is only just now beginning to take form. This is going to be a real catalyst for taking things up a notch—expanding our entire portfolio and, in particular, VEVYE as we move ahead. We're noticing more prescribers, improved productivity, and a greater volume of prescriptions.

Thomas Flaten

analyst
#60

That's excellent. Thank you all.

Jeffrey Cohen

analyst
#61

Hi there, good morning. Appreciate you taking our questions. Two from Amir, I suppose. First off, perhaps for Mark or Amir, could you discuss the TRIESENCE phase III and its enrollment—how is it progressing, when might we expect it to finish, and what should we anticipate regarding press releases or filing dates?

Mark Baum

executive
#62

Certainly. Amir, would you like to address that trial?

Amir Shojaei

executive
#63

Yeah, thanks for asking that. Things are progressing nicely with our TRIESENCE program. Enrollment is where we expect it to be. We continue to expect the readout next year — more precisely, late in the first quarter or early in the second quarter; that's roughly where we stand right now.

Jeffrey Cohen

analyst
#64

Perfect. Okay, thank you for that. Second, I suppose this one's directed at Andrew. Would you be able to discuss R&D for the quarter and perhaps give us some idea of what you anticipate on R&D, maybe for Q4, or simply in general terms regarding the levels? I know you've been pretty busy across a number of areas on the development front.

Andrew Boll

executive
#65

Yeah. Thanks, Jeff. Regarding R&D, R&D is, I'd say, almost a seasonal kind of spend; it hinges on what we have active and what we're able to speed up. But normally, the expense, I believe, as a percentage of revenue ought to be about the same as it stands right now. That's what we're going to attempt to anchor it to; however, if opportunities arise to accelerate or investments come along that we believe can deliver a meaningful return, we'll pursue them. As we're sort of examining Q4, we're speeding up some of these programs. We have accelerated programs. Not all of that lands in R&D, by the way. A portion of it rises into the SG&A line; for instance, with the G-MELT NDA filing, not all of that cost that will go into that filing and the PDUFA fee that accompanies it is going to land in R&D. There will be portions of it certainly, but other portions will likewise flow up into SG&A.

Jeffrey Cohen

analyst
#66

Great. Appreciate you fielding the questions.

Andrew Boll

executive
#67

Thanks, Jeff.

Mark Baum

executive
#68

Thanks, operator, and I appreciate all of you being here. Real momentum is building as we head toward what we anticipate will be Harrow's best quarter; we're eager to share our full-year results and hope to see plenty of you at our Investor Day in New York City in March. Have a great day.

Operator

operator
#69

This concludes today's conference call. Thank you for participating, and you may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Harrow, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Harrow, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Harrow, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.